Clinical Trial Update: Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial updating efficacy of lazertinib with pemetrexed and carboplatin after osimertinib failure in non-small cell lung cancer with brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Lazertinib (lazertinib)
• Osimertinib (osimertinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Jin Hyoung Kang | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN